Home LiteratureArticle Details
PMID: 19073420 Published · ppublish English Journal Article Review

Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.

Neurotoxicity research ·Vol. 14 ·No. 2-3 ·2008-10-00 ·Pages 121-8

Kostrzewa RM, Kostrzewa JP, Brown RW, Nowak P, Brus R

Abstract

The process of receptor supersensitivity (RSS) has a long history and is an epiphenomenon of neuronal denervation. Dopamine (DA) RSS (DARSS) similarly occurs after DA denervation, and this process is invoked in neuropsychiatric and neurodegenerative disorders. From studies largely over the past 25 years, much has been learned regarding DARSS. For example, overt D1 DARSS occurs after perinatal destruction of nigrostriatal DA fibers. However, following perinatal destruction of DA innervation, the most-prominent behavioral effects of a D1 agonist are observed after a series of D1 agonist treatments--a process known as priming of D1 DA receptors. Moreover, perinatal lesioning of DA fibers produces prominent serotonin (5-HT) RSS, and in fact 5-HT RSS appears to modulate D1 DA RSS. In rodents, receptor supersensitization by these means appears to be irreversible. In contrast to the observed D1 DARSS, D2 DARSS apparently does not occur after perinatal DA denervation. Also, while repeated D1 agonist treatment of intact rats has no observable effect, repeated D2 agonist treatments, during or after the ontogenetic phase, produces prominent life-long D2 RSS. The process may have an association with substance abuse. Therefore, production of D1 and D2 DARSS occurs by different means and under different circumstances, and in association with perhaps different neuronal phenotypes, and with greater incidence in either intact (D2) or DA-lesioned counterparts (D1). The physiological consequence of RSS are multiple.

MeSH Terms
5,7-Dihydroxytryptamine/pharmacology Age Factors Animals Animals, Newborn Behavior, Animal/drug effects Denervation Oxidopamine/pharmacology Rats Receptors, Dopamine D1/agonists,drug effects,physiology Receptors, Dopamine D2/agonists,drug effects,physiology Receptors, Serotonin/drug effects,physiology Striatonigral Degeneration/chemically induced
Chemicals
Receptors, Dopamine D1 Receptors, Dopamine D2 Receptors, Serotonin 5,7-Dihydroxytryptamine Oxidopamine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Kostrzewa Richard M
Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA. kostrzew@etsu.edu
Kostrzewa John P
Brown Russell W
Nowak Przemyslaw
Brus Ryszard
References (62)
62 references, click to expand
  1. 7-OH-DPAT, unlike quinpirole, does not prime a yawning response in rats.
    Pharmacol Biochem Behav. 2000 Sep;67(1):11-5 PMID: 11113478
  2. Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction.
    Science. 1976 Jan 23;191(4224):305-8 PMID: 942800
  3. Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats.
    Brain Res Dev Brain Res. 1993 Nov 19;76(1):59-65 PMID: 8306431
  4. Enhanced pilocarpine-induced oral activity responses in neonatal 6-OHDA treated rats.
    Pharmacol Biochem Behav. 1993 Jul;45(3):737-40 PMID: 8332633
  5. Changes in the development of central noradrenaline neurones following neonatal administration of 6-hydroxydopamine.
    J Neurochem. 1974 Mar;22(3):419-26 PMID: 4829965
  6. A dopamine deficiency model of Lesch-Nyhan disease--the neonatal-6-OHDA-lesioned rat.
    Brain Res Bull. 1990 Sep;25(3):477-84 PMID: 2127238
  7. Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat.
    Brain Res Bull. 1987 Aug;19(2):269-74 PMID: 3664282
  8. Hypersensitivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation.
    Eur J Pharmacol. 1994 Aug 11;261(1-2):171-8 PMID: 8001641
  9. Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats.
    Eur J Pharmacol. 1994 Dec 27;271(2-3):433-7 PMID: 7705443
  10. DSP-4 prevents dopamine receptor priming by quinpirole.
    Pharmacol Biochem Behav. 2006 May;84(1):3-7 PMID: 16675001
  11. Obsessive-compulsive disorder as a disturbance of security motivation: constraints on comorbidity.
    Neurotox Res. 2006 Oct;10(2):103-12 PMID: 17062372
  12. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    J Pharmacol Exp Ther. 1987 Jan;240(1):167-76 PMID: 3100767
  13. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    J Pharmacol Exp Ther. 1992 Aug;262(2):855-65 PMID: 1354257
  14. Validation of the transporter ligand cyanoimipramine as a marker of serotonin innervation density in brain.
    J Nucl Med. 1994 Nov;35(11):1822-30 PMID: 7965165
  15. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats.
    J Neurosci. 1989 Jan;9(1):125-33 PMID: 2521511
  16. Neurodevelopmental liabilities of substance abuse.
    Neurotox Res. 2002 Jun;4(4):267-79 PMID: 12829418
  17. Low-dose quinpirole ontogenically sensitizes to quinpirole-induced yawning in rats.
    Pharmacol Biochem Behav. 1993 Feb;44(2):487-9 PMID: 8095344
  18. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system.
    Acta Physiol Scand Suppl. 1971;367:95-122 PMID: 4332694
  19. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications.
    Int Rev Neurobiol. 1989;31:1-79 PMID: 2689379
  20. Neonatal 6-hydroxydopamine and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats.
    J Neurochem. 1994 Oct;63(4):1282-90 PMID: 7931280
  21. Enhanced quinpirole response in rats lesioned neonatally with 5,7-dihydroxytryptamine.
    Pharmacol Biochem Behav. 1995 Apr;50(4):649-53 PMID: 7617714
  22. Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats.
    Psychopharmacology (Berl). 1995 Jun;119(4):466-73 PMID: 7480527
  23. Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain.
    J Neurochem. 1998 Mar;70(3):889-98 PMID: 9489707
  24. Serotonin neurotoxins--past and present.
    Neurotox Res. 2004;6(7-8):589-614 PMID: 15639791
  25. Sprouting of noradrenergic terminals in rat cerebellum following neonatal treatment with 6-hydroxydopa.
    Brain Res. 1977 Mar 25;124(2):385-91 PMID: 843956
  26. Induction of oral dyskinesias in naive rats by D1 stimulation.
    Life Sci. 1983 Dec 19;33(25):2479-82 PMID: 6227782
  27. Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA.
    Pharmacol Biochem Behav. 1991 Jul;39(3):677-82 PMID: 1686103
  28. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system.
    J Pharmacol Exp Ther. 1992 Jun;261(3):1000-7 PMID: 1602367
  29. Effect of 6-hydroxydopa on catecholamine-containing neurons in brains of newborn rats.
    Brain Res. 1974 Mar 29;69(1):174-81 PMID: 4817911
  30. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
    J Pharmacol Exp Ther. 1985 Nov;235(2):287-95 PMID: 3932640
  31. Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats.
    Pharmacol Biochem Behav. 1992 Mar;41(3):621-3 PMID: 1584843
  32. Evaluation of the effects of 5,7-dihydroxytryptamine on serotonin and catecholamine neurons in the rat CNS.
    Acta Physiol Scand Suppl. 1973;391:1-19 PMID: 4521070
  33. Quantification of the serotonin hyperinnervation in adult rat neostriatum after neonatal 6-hydroxydopamine lesion of nigral dopamine neurons.
    Brain Res. 1995 Jan 16;669(2):303-8 PMID: 7712186
  34. Ontogenic homologous supersensitization of quinpirole-induced yawning in rats.
    Pharmacol Biochem Behav. 1991 Jun;39(2):517-9 PMID: 1682952
  35. Amphetamine-induced enhancement of neostriatal in vivo microdialysate dopamine content in rats, quinpirole-primed as neonates.
    Pol J Pharmacol. 2001 Jul-Aug;53(4):319-29 PMID: 11990078
  36. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    J Pharmacol Exp Ther. 1985 Aug;234(2):447-55 PMID: 3926987
  37. Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats.
    Brain Res. 1985 Jun 17;336(2):354-8 PMID: 3924346
  38. Ontogenetic quinpirole treatment induces vertical jumping activity in rats.
    Eur J Pharmacol. 1993 Aug 3;239(1-3):183-7 PMID: 7901028
  39. Changes of D1 and D2 receptors in adult rat neostriatum after neonatal dopamine denervation: quantitative data from ligand binding, in situ hybridization and iontophoresis.
    Neuroscience. 1993 Dec;57(3):635-48 PMID: 7906013
  40. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.
    Neurotox Res. 2003;5(5):329-38 PMID: 14715452
  41. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment.
    J Pharmacol Exp Ther. 1994 Jan;268(1):231-7 PMID: 8301563
  42. Dopamine receptor supersensitivity.
    Neurosci Biobehav Rev. 1995 Spring;19(1):1-17 PMID: 7770190
  43. Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine.
    Brain Res. 1992 Jan 8;569(1):1-13 PMID: 1611468
  44. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    J Pharmacol Exp Ther. 1984 Nov;231(2):343-54 PMID: 6149306
  45. Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: an anatomical, biochemical and pharmacological study.
    Pharmacol Biochem Behav. 1989 Oct;34(2):367-74 PMID: 2576138
  46. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.
    Acta Physiol Scand Suppl. 1971;367:49-68 PMID: 4332692
  47. Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study.
    J Comp Neurol. 1986 Mar 8;245(2):274-81 PMID: 2420842
  48. Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas.
    Eur J Pharmacol. 1975 Mar;31(1):1-16 PMID: 1168579
  49. Proposed animal model of attention deficit hyperactivity disorder.
    Brain Res Bull. 1994;34(2):161-7 PMID: 7913871
  50. Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats.
    Brain Res Dev Brain Res. 1993 Nov 19;76(1):87-93 PMID: 8306435
  51. Pharmacological actions of 6-hydroxydopamine.
    Pharmacol Rev. 1974 Sep;26(3):199-288 PMID: 4376244
  52. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates.
    J Pharmacol Exp Ther. 1997 Jan;280(1):268-76 PMID: 8996206
  53. Elevation of dopamine D2 but not D1 receptors in adult rat neostriatum after neonatal 6-hydroxydopamine denervation.
    Brain Res. 1990 Dec 17;536(1-2):287-96 PMID: 2150772
  54. Effects of 6-hydroxydopa on noradrenergic neurons in developing rat brain.
    J Pharmacol Exp Ther. 1976 Apr;197(1):105-18 PMID: 1263125
  55. Ontogenetic homologous sensitization to the antinociceptive action of quinpirole in rats.
    Eur J Pharmacol. 1991 Dec 17;209(3):157-61 PMID: 1686767
  56. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles.
    Brain Res Brain Res Rev. 2005 Feb;48(1):57-73 PMID: 15708628
  57. Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6-hydroxydopamine.
    J Pharmacol Exp Ther. 1994 Aug;270(2):713-21 PMID: 8071864
  58. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study.
    Brain Res. 1993 Mar 26;606(2):273-85 PMID: 8490720
  59. Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats.
    Brain Res Dev Brain Res. 1993 Dec 17;76(2):233-8 PMID: 8149589
  60. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.
    Acta Physiol Scand Suppl. 1971;367:69-93 PMID: 4332693
  61. Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine.
    Nature. 1976 May 13;261(5556):153-5 PMID: 944861
  62. Lateromedial gradient of the susceptibility of midbrain dopaminergic neurons to neonatal 6-hydroxydopamine toxicity.
    Exp Neurol. 1995 Dec;136(2):136-42 PMID: 7498403
Article Info
Journal
Neurotoxicity research
Abbr.
Neurotox Res
ISSN
1029-8428
Published
2008-10-00
Pages
121-8
Language
English
Region
United States
NLM ID
100929017
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com